


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. St. Joseph Health System LLC d/b/a St. Joseph Hospital</p> <p>2. 700 Broadway Fort Wayne, IN 46802</p>		<p>In accordance with letter dated July 15, 2021,</p>	<p>4. Expiration Date: October 31, 2036</p>
		<p>3. License No.: 13-00418-02 is renewed in its entirety to read as follows:</p>	<p>5. Docket No.: 030-01581 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.500</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Biosource/Gammatron, Inc., Model OS-213A)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 300 millicuries per source and 300 millicuries total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For storage only incident to disposal.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-00418-02

Docket or Reference No.:
030-01581

Amendment No. 65

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at
 A. St. Joseph Hospital, 700 Broadway, Fort Wayne, Indiana, 46802
 B. Lutheran Downtown Hospital, 702 Van Buren St., Fort Wayne, Indiana, 46802
11. The Radiation Safety Officer (RSO) for this license is Andre B. Stovall, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D., D.O., etc.)

Material and Use

Sandeep S. Ahluwalia, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

James A. Arata, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300, 10 CFR 35.500

John H. Arnett, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.500

Jonathon Berger, M.D.

10 CFR 35.100, 10 CFR 35.200

H. Steven Beyer, M.D.

10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

John L. Bormann, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300, 10 CFR 35.500

Daniel Branam, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Joseph R. DeCamp, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Brett Hagedorn, M.D.

10 CFR 35.100, 10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-00418-02

Docket or Reference No.:

030-01581

Amendment No. 65

Authorized User (M.D.,D.O.,etc.)Material and Use

Eric V. Heatwole, M.D.	10 CFR 35.100,10 CFR 35.200
Linda Gould Hippenhammer, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
David B. Janizek, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300,10 CFR 35.500
Shawn Johnson, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Shilpa Kashyap, M.D.	10 CFR 35.100,10 CFR 35.200
Christopher Kowalski, M.D.	10 CFR 35.100,10 CFR 35.200
John C. Lacunza, M.D.	10 CFR 35.100,10 CFR 35.200
Michael E. Parker, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300,10 CFR 35.500
John Pasalich, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300,10 CFR 35.500
Dakshesh Patel, M.D.	10 CFR 35.100,10 CFR 35.200
Randall J. Phillips, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300,10 CFR 35.500
John Rock, M.D.	10 CFR 35.100,10 CFR 35.200
Eugene Shih	10 CFR 35.100,10 CFR 35.200
Richard Sibley, M.D.	10 CFR 35.100,10 CFR 35.200
David Sorg, M.D.	10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)
Richard P. Stephens, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300,10 CFR 35.500
Andre B. Stovall, M.D.	10 CFR 35.100,10 CFR 35.200
Pamela Lee Strange, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300,10 CFR 35.500; 10 CFR 35.100, 35.200, 35.300, and 35.500
Marc Thomas, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300,10 CFR 35.500
Frederick N. Vandeman, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.500; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)
James C. Wehrenberg, M.D.	10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 13-00418-02

Docket or Reference No.:
030-01581

Amendment No. 65

13. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

A. Letter dated July 15, 2021 (ML21218A064)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: October 15, 2021

By: _____

Laura B. Cender
Region 3